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Despite marked advances in the understanding of allergic re-
sponses, the mechanisms regulating gastrointestinal allergy are
not very well understood. We have developed a model of
antigen-induced eosinophil-associated gastrointestinal allergy
and characterized the role of eotaxin and IL-5. Challenge of
allergen-sensitized mice with oral allergen, in the form of
enteric-coated beads, resulted in marked allergen-specific IgG1
and IgE, Th2-type (IL-4 and IL-5) cytokine production, and eosin-
ophil accumulation in the blood and small intestine. In the
genetic absence of eotaxin, a chemokine constitutively ex-
pressed in the gastrointestinal tract, eosinophil recruitment into
the small intestine was ablated, and these mice developed
enhanced eosinophil accumulation in the blood compared with
wild-type mice. Interestingly, in the absence of IL-5, allergen
challenge promoted partial eosinophil accumulation into the
small intestine and a decline in circulating eosinophil levels.
Collectively, these results establish that the accumulation of
gastrointestinal eosinophils is antigen induced, can occur inde-
pendent of IL-5, and provides a molecular mechanism to explain
the dichotomy between peripheral blood and tissue eosino-
philia. Furthermore, eotaxin is identified as a critical regulator of
antigen-induced eosinophilic inflammation in the gastrointesti-
nal tract.
A llergic diseases have reached epidemic proportions in theWestern world, affecting nearly 30 percent of the population
(1). Interestingly, this increased prevalence is paralleled by an
increase in the severity and spectrum of disorders involving hyper-
sensitivity responses in various tissues (e.g., the gastrointestinal
tract). Although substantial progress has been made in elucidating
the inflammatory mechanisms involved in allergic responses in the
lung, there has been limited progress in understanding the patho-
genesis of allergic disorders of the gastrointestinal tract. The
development of experimental models of allergy has provided
important insights into the immunological mechanisms regulating
systemic (e.g., anaphylaxis) and pulmonary (e.g., asthma) allergic
diseases. Collectively, these studies have identified a central role for
cytokines (e.g., IL-4, IL-5, and IL-13), CD41 T cells, mast cells, and,
in particular, eosinophils, in the induction and sustainment of
allergic inflammatory responses (2).
Eosinophil accumulation in the peripheral blood and tissues is
a hallmark of allergic responses, and clinical investigations have
established a strong link between the pathobiology of several
allergic disorders and eosinophil accumulation and activation
(3). However, it remains to be determined why some disease
states are characterized by peripheral blood eosinophilia,
whereas others are associated with a tissue eosinophilia in the
presence or absence of peripheral blood eosinophilia. Although
most studies have demonstrated an integral role for the cytokine
IL-5 in eosinophil trafficking during allergic inflammatory re-
sponses, chemokines have also been recently implicated in the
regulation of eosinophil accumulation (4–6). In particular,
eotaxin has been identified as a potent and selective eosinophil
chemoattractant and has been implicated in the pathogenesis of
human allergic disease (7). However, in contrast to mice defi-
cient in IL-5, aeroallergen challenge of eotaxin-deficient mice
induces eosinophilic airway inflammation (8–10). Collectively,
these data suggest that in comparison to eotaxin and other
CCR3-ligands, IL-5 plays an obligatory role in regulating eosin-
ophil trafficking during allergic responses in the lung.
There are a spectrum of eosinophil-associated inflammatory
responses in the gastrointestinal tract, including IgE-mediated food
anaphylaxis, inflammatory bowel disease, gastroesophageal reflux,
allergic eosinophilic gastroenteritis, and eosinophilic colitis (11). It
is currently thought that eosinophils may augment and sustain the
gastrointestinal inflammatory response through the release of
inflammatory mediators andyor granule cationic proteins that are
toxic to the mucosa (11–14). However, although there have been
recent advances in modeling some of these disease processes (e.g.,
IgE-mediated anaphylaxis responses), there have been only limited
models of eosinophil-associated gastrointestinal allergy, and the
precise mechanisms regulating gastrointestinal eosinophilia and the
immunopathological role of this leukocyte in gastrointestinal dis-
orders remain an enigma (11, 13, 15). To elucidate these processes,
we have developed a murine model of eosinophil-associated gas-
trointestinal allergy and examined the role of eotaxin and IL-5 in
the regulation of eosinophil trafficking.
Methods
Animals. Eotaxin-deficient inbred mice of the (129ySvEv) strain
were maintained with age, and sex-matched controls were
obtained from Taconic Farms as previously described (9).
IL-5-deficient inbred mice of the (BALByc) strain and age and
sex-matched controls were kindly provided by K. Matthaei (John
Curtin School of Medical Research, Canberra, Australia) (8).
Mice were sensitized by i.p. injection with 50 mg ovalbumin
(OVA)y1 mg alum in 0.9% sterile saline on day 0. On days 12 and
15, mice were lightly anesthetized with Metofane inhalation
(methoxy-fluorane; Pittman–Moore, Mundelein, IL) and orally
administered 20 mg of encapsulated OVA enteric-coated beads
or encapsulated placebo enteric-coated beads followed by oral
administration of 300 ml of acidified H20 (pH 2.0) (16). Seventy-
two hours after the last antigen challenge, mice were killed by
cervical dislocation and parameters measured.
ELISA Measurements. Serum OVA-specific IgG1 and IgE concen-
trations were determined by ELISA. Sample wells were coated with
OVA (100 mgyml) for IgG1 or anti-mouse IgE (EM-95; 10 mgyml;
gift from F. Finkelman, University of Cincinnati, Cincinnati, OH),
blocked with 10% FBS in PBS, and washed with 0.05% Tween-20
in PBS. Serum samples were diluted 1:5 for IgE and 1:1,000 for IgG1
with 10% FCS in PBS and serially diluted (1:2). After a 2-h
incubation at 37°C, plates were washed with 0.05% Tween-20 in
PBS, and biotin-conjugated anti-mouse IgG1 (clone: A85–1; 0.5
mgyml; PharMingen) or biotinylated OVA (4 mgyml) was added. By
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using streptavidin horseradish peroxidase detection (2 mgyml;
ImmunoTech, Marseilles, France), the OD was read at 490 nm
within 30 min. Data represent mean 6 SEM of the serum dilution
required to obtain an OD 5 0.4. Values are representative of n 5
4–5 mice per group from triplicate experiments.
Antigen-Specific T-Cell Response. Splenocytes were subjected to
OVA or aCD3yaCD28 stimulation as previously described (17).
For proliferation experiments, splenocyte cultures were pulsed with
1 mCi [3H]-thymidine for the last 6 h of a 72-h culture. IL-4, IL-5,
and IFNg levels were determined in the supernatants from OVA-
(50 mgyml) or aCD3- (5 mgyml)yaCD28 (1 mgyml) stimulated
splenocytes homogenates by using the OptEIA Mouse IL-4 and
IL-5 kits (PharMingen), respectively. The IFNg level was measured
by using rat anti-mouse IFNg mAb (PharMingen; 5 mgyml, clone;
R4–6A2). The sensitivity of the ELISA system was 20 pgyml for
IL-4 and IL-5 and 100 pgyml for IFNg.
Immunohistochemistry. The small intestine of mice was divided
into the duodenum, jejunum, and ileum, and segments of the
gastrointestinal tract were fixed with paraformaldehyde, pro-
cessed by using standard histological techniques, and immuno-
stained with antiserum against mouse major basic protein
(MBP) as previously described (18). Briefly, 5-mm sections were
quenched with H202, blocked with normal goat serum, and
stained with a rabbit antimurine eosinophil MBP antiserum (gift
of J. and N. Lee, Mayo Clinic, Scottsdale, AZ). The slides were
washed and incubated with biotinylated goat anti-rabbit antibody
and avidin–peroxidase complex (Vectastain ABC Peroxidase
Elite kit; Vector Laboratories). The slides were then developed
by nickel diaminobenzidine, enhanced cobalt chloride to form a
black precipitate, and counterstained with nuclear fast red.
Quantification of immunoreactive cells was performed by mor-
phometric analysis by using the Metamorph Imaging System
(Universal Imaging, West Chester, PA). The sections were taken
Fig. 1. Characterization of gastrointestinal allergy in
wild-type and eotaxin-deficient mice. (A) Experimental re-
gime. Mice were i.p. injected with 50 mg OVAy1 mg alum
on day 0. On days 12 and 15, mice were orally administered
20 mg of encapsulated placebo- and OVA-enteric coated
beads followed by acidified H2O (pH 2.0). Four days after
the last challenge, mice were killed and parameters mea-
sured. (B) Eosinophil numbers in the peripheral blood of
placebo- and oral-allergen-challenged wild-type (WT) and
eotaxin-deficient (eotaxin2/2) mice. Inset specifies the
groups. (C and D) Levels of allergen-specific IgE (C) and IgG1
(D) in the serum of placebo- and oral allergen-challenged
wild-type (WT) and eotaxin-deficient (eotaxin2/2) mice
were determined by ELISA. (E) Proliferation of splenic T
cells stimulated by aCD3yaCD28 or OVA were measured by
[3H]-thymidine incorporation. (F–H) Secretion of IL-4 (F),
IL-5 (G), and IFNg (H) by aCD3yaCD28- and OVA-stimulated
splenic T cells. Data in B and D represent the mean 6 SEM
for groups of four to five animals in triplicate experiments
and (E–H) mean 6 SEM from three individual cultures
obtained from four to five mice in each group. Statistical
significance of experimental groups was analyzed by using
the unpaired Student’s t test (B). *, P , 0.05 compared with
day 19 allergen challenge of wild-type mice; 1, P , 0.001
compared with placebo challenge of wild-type mice on day
19. Unless otherwise indicated, data were obtained on day
19. ND, not detected.
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from the same position in the jejunum (3–5 cm distal to the
stomach), and at least four to five random sections per mouse
were analyzed. Values were determined by quantifying the total
MBP1 pixel number relative to the total pixel counts of the
lamina propria and mucosa regions of the gastrointestinal tissue.
Eosinophil levels are expressed as the MBP stainingyarea (%).
FACS Analysis on Peripheral Blood Eosinophils. Peripheral blood was
subjected to red blood cell lysis, and cells (106) were incubated
with 1 mg phycoerythrin-conjugated anti-mouse LPAM-1 (In-
tegrin a4b7 complex; DATK32; PharMingen) and FITC-
conjugated anti-mouse CCR3 mAb (1y200; DNAX) or the
isotype-matched control antibodies at 4°C (19). Cells were
analyzed on a FACScan Flow cytometer (Becton Dickinson) by
using CELLQUEST software (Becton Dickinson).
Results
Development of Experimental Antigen-Induced Eosinophilic Gastro-
intestinal Allergy. One of the complexities of inducing allergic
inflammation of the gastrointestinal tract is the ineffectiveness of
orally administered soluble protein antigens in promoting hyper-
sensitivity responses; rather, oral antigens generally promote im-
munological tolerance (20). The poor immune response and in-
duction of oral tolerance is thought to be associated, at least in part,
with gastric digestion of soluble protein antigens, which leads to the
formation of nonimmunogenic peptides (21, 22). To overcome
immunological tolerance associated with oral administration of
soluble antigens (23, 24), we used a system whereby a soluble
protein antigen was encapsulated to protect against gastric digestion
(16). The encapsulated biodegradable antigen particles are resistant
to degradation at gastric pH (pH 2.5); however, they are susceptible
Fig. 2. Histological analysis of jejunum tissue from placebo- and oral allergen-challenged wild-type and eotaxin-deficient mice. (A and B) Photomicrographs
represent hemataoxylin- and eosin-stained jejunum sections from placebo- (A) and oral allergen- (B) challenged wild-type mice. (C and D) Photomicrographs
represent rabbit anti-mouse MBP [aMBP]-immunostained jejunum sections from placebo- (C) and oral allergen- (D) challenged wild-type mice. (E and F)
Photomicrographs represent anti-MBP-stained jejunum sections from placebo- (E) and oral allergen- (F) challenged eotaxin-deficient mice. In placebo-challenged
wild-type mice (C), eosinophils are predominantly localized to the crypt region and less frequently within the lamina propria of the villus. In oral allergen-
challenged wild-type mice (B and D) but not eotaxin-deficient mice (F), an eosinophilic infiltrate is observed. Eosinophils are present within the mucosa and
throughout the length of the villus. Arrows depict representative eosinophils. (A and B, 3950; C–F, 3460.)









to degradation at pH 5.5, which facilitates the delivery and release
of the allergen in a preserved native conformational state to the
small intestine (16). Extensive previous investigations have dem-
onstrated that the particles may overcome immunological tolerance
associated with oral administration of antigens and possess adjuvant
and immunostimulatory activity promoting antigen-specific anti-
body production (25).
Mice were injected i.p. with the egg antigen OVA in the presence
of adjuvant (alum) and subsequently challenged with oral OVA
particles on days 12 and 15 (Fig. 1A). Administration of oral
allergen to sensitized mice induced peripheral blood eosinophilia
and allergen-specific IgE and IgG1, but not IgG2a, antibody re-
sponses (Fig. 1 B–D; data not shown). On day 19, the level of
eosinophils in the peripheral blood of oral allergen-challenged mice
was 3.5-fold higher than in placebo-challenged mice (Fig. 1B). To
establish whether the peripheral blood eosinophilia and antigen-
specific IgE was associated with the development of a CD41
Th2-type immune response, proliferation and cytokine responses by
splenic T cells from oral allergen- or placebo-challenged mice were
determined (Fig. 1 E–H). Allergen stimulation induced a significant
proliferation response in the oral allergen-challenged mice but not
the control group (Fig. 1E). In contrast, the proliferation responses
of T cells to nonspecific polyclonal activation (aCD3yaCD28) was
comparable between placebo- and oral allergen-challenged mice
(Fig. 1E). To characterize the phenotype of the allergen-reactive T
cells, IL-4, IL-5, and IFNg levels in the splenocyte cultures were
measured (Fig. 1 F–H). The addition of OVA to the T cells of oral
allergen-challenged mice induced the production of IL-4 and IL-5,
but no detectable IFNg, a cytokine produced by Th1 cells. In
contrast, splenocytes isolated from placebo-challenged mice pro-
duced only low levels of IL-5 and no detectable IL-4 or IFNg (Fig.
1 F–H). Collectively, these data indicated that oral allergen chal-
lenge promoted the expansion of a Th2-biased immune response.
Histological examination of the jejunum revealed vascular
congestion, edema, and a prominent cellular infiltrate in the oral
allergen-challenged mice as compared with placebo-challenged
mice (Fig. 2 A and B). The cellular infiltrate was predominantly
localized to the mucosa and lamina propria throughout the small
intestine and was primarily composed of eosinophils (Fig. 2B,
and results not shown). Elevated levels of eosinophils were also
observed in the duodenum and ileum of oral allergen-challenged
mice as compared with placebo-challenged mice (results not
shown). The presence of eosinophils was further characterized by
standard immunohistochemical analysis by using an antiserum
specific for eosinophils (anti-MBP) (Fig. 2 C and D). The
infiltrating eosinophils were observed interspersed throughout
the reticular connective tissue of the lamina propria and mucosa
and throughout the length of the lamina propria of the villi (Fig.
2 B and D). Placebo-challenged mice had low levels of eosino-
phils predominantly localized to the base of the villus in the
region of the crypt of Lieberku¨hn and occasional cells within the
lamina propria of the villus (Fig. 2 A and C). This distribution is
similar to the location of eosinophils at baseline (naı¨ve mice),
indicating that placebo challenge alone did not significantly
affect eosinophil trafficking (18). Morphometric analysis re-
vealed that the level of eosinophils in oral allergen-challenged
mice was significantly higher (P , 0.0001) than that observed in
placebo-challenged mice (Fig. 3). Because mast cells have also
been implicated in the pathogenesis of various gastrointestinal
hypersensitivity responses (11, 13), we were interested in exam-
ining their participation in oral antigen-induced eosinophil
gastrointestinal allergy. Histological analysis of the jejenum
revealed no significant difference in the level of mast cells within
the lamina propria and villus between placebo-challenged and
oral allergen-challenged mice (results not shown).
Critical Role of Eotaxin in Antigen-Induced Experimental Eosinophilic
Gastrointestinal Allergy. Elevated levels of eotaxin and eosinophils
have been associated with various human inflammatory disorders,
and increased levels correlate with disease severity (26, 27). Thus,
it was critical to determine the role of this chemokine and gastro-
intestinal eosinophils in gastrointestinal allergic inflammation. Oral
allergen challenge of eotaxin-deficient mice induced a marked
increase in peripheral blood eosinophils compared with placebo-
challenged eotaxin-deficient mice (Fig. 1B). Interestingly, the pe-
ripheral blood eosinophilia was significantly higher than that of oral
allergen-challenged wild-type mice (Fig. 1B). We hypothesized that
the elevated level of eosinophils in the peripheral blood of oral
allergen-challenged eotaxin-deficient mice was because of failure to
recruit eosinophils to the gastrointestinal tract, thus preventing the
transmigration of circulating eosinophils into the site of inflamma-
tion. To test this hypothesis, we examined the level of eosinophils
in the lamina propria of the small intestine of oral allergen-
challenged eotaxin-deficient mice. Histological analysis of the in-
testinal tissue from oral allergen-challenged mice revealed no
significant morphological changes to the small intestine structural
integrity in the absence of eotaxin (Fig. 2F; data not shown).
Morphometric analysis of anti-MBP-stained tissue revealed that in
contrast to wild-type mice, oral allergen challenge of eotaxin-
deficient animals induced no significant increase in the level of
eosinophils as compared with placebo-challenged eotaxin-deficient
mice (Fig. 3). The level of eosinophils in oral allergen-challenged
eotaxin-deficient mice was markedly reduced compared with wild-
type mice (P , 0.001) (Fig. 3). This indicates that the reduced
baseline level of gastrointestinal lamina propria eosinophils in
eotaxin-deficient mice is not increased by allergen challenge (28).
The reduction of intestinal inflammation in the absence of eotaxin
was not because of the failure to develop allergen-specific lympho-
cyte responses, because eotaxin-deficient mice produced marked
levels of allergen-specific IgE and IgG1 (Fig. 1 C and D) and Th2
cytokines (data not shown).
Normal Levels of CCR-3 and a4b7 in the Absence of Eotaxin. We next
examined the mechanism for the impaired recruitment of eosino-
phils into the gastrointestinal tract in the absence of eotaxin. Recent
investigations have demonstrated that other chemokines, including
RANTES, may induce eosinophil chemotaxis via the eotaxin
receptor, CC-chemokine receptor 3 (CCR3) (6, 29, 30). To deter-
mine whether ablation of eosinophil transmigration was specific for
Fig. 3. Quantification of gastrointestinal eosinophils by morphometric analysis
in placebo- and oral allergen-challenged wild-type and eotaxin-deficient mice.
Gastrointestinal eosinophil numbers were quantified in placebo- and oral aller-
gen-challenged wild-type (WT) and eotaxin-deficient (eotaxin2/2) mice by mor-
phometric analysis. Data were obtained on day 19. Data represent the mean 6
SEMoffour tofiverandomsectionsymousefor four tofiveanimalspergroupand
are representative of three separate experiments. Statistical significance of ex-
perimental groups was analyzed by using the unpaired Student’s t test.
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eotaxin and was not because of a loss of CCR3, we examined the
level of expression of CCR3 on peripheral blood eosinophils from
oral allergen-challenged wild-type and eotaxin-deficient mice. We
observed no difference in the level of CCR3 expression between
wild-type and eotaxin-deficient mice, suggesting that eotaxin was
not required for CCR3 expression [the mean fluorescence intensity
for CCR3 was 23.8 and 21.8 for eosinophils from wild-type and
eotaxin-deficient mice, respectively; see supplementary data (ww-
w.pnas.org)]. We also examined the level of expression of the
eosinophil adhesion molecule, a4b7, because this integrin has been
shown to be responsible for the recruitment of leukocytes into the
intestinal lamina propria and associated lymphatic organs (31, 32).
Eosinophils from the peripheral blood of oral allergen-challenged
wild-type mice expressed a4b7 at the same level as eosinophils from
eotaxin-deficient allergen-challenged mice (the mean fluorescence
intensity for a4b7 was 8.56 and 9.82 for eosinophils from wild-type
and eotaxin-deficient mice, respectively; see supplementary data).
Collectively, these results suggest that the failure to recruit eosin-
ophils into the intestine of allergen-challenged mice is most likely
because of loss of the eotaxin concentration gradient in the
intestine.
The Role of IL-5 in Experimental Eosinophilic Gastrointestinal Allergy.
We were next interested in determining the role of IL-5 in regu-
lating eosinophil-associated gastrointestinal allergy because this
cytokine is a pivotal modulator of eosinophil trafficking during
allergic airways inflammation (8, 17, 33, 34). IL-5 has been shown
to mobilize eosinophils from the bone marrow into the circulation
and to promote eosinophil tissue trafficking during allergic airway
inflammation (8, 35, 36). We therefore compared oral allergen-
induced gastrointestinal allergy in IL-5-deficient and wild-type
mice. In marked contrast to wild-type mice, allergen challenge of
IL-5-deficient mice did not promote a peripheral blood eosinophilia
(Fig. 4 A and B). Interestingly, after the second allergen challenge
(day 19), the level of eosinophils in the blood of these mice was
significantly lower than that of placebo-challenged IL-5-deficient
mice (P , 0.05; Fig. 4B). Levels of allergen-specific IgE and IgG1
resembled those present in wild-type mice (Fig. 4 C and D). These
data suggest that the limited number of circulating eosinophils
present in IL-5-deficient animals were being recruited into the
intestine after allergen challenge, thereby depleting the level of
peripheral blood eosinophils. To prove this, morphometric analysis
of anti-MBP staining of IL-5-deficient mice revealed a 3-fold
increase in the level of eosinophils recruited into the intestine after
allergen challenge (Fig. 4E). The level of eosinophil recruitment
was still lower than in allergen-challenged wild-type mice. These
studies also indicated that the baseline production of eosinophils,
which occurs independently of known eosinophil hematopoietins
(IL-3, IL-5, and GM-CSF) (18), provides a sufficient number of
eosinophils for the development of tissue eosinophilia.
Discussion
We have developed a model for oral allergen-induced eosinophil-
associated gastrointestinal allergy that mimics a variety of human
gastrointestinal allergic conditions. Although no murine model
adequately mimics human disease, our experimental regime offers
an experimental framework to analyze the events associated with
antigen-induced eosinophil-associated gastrointestinal allergy. Our
results establish that oral allergen is sufficient to promote the
recruitment of eosinophils to the gastrointestinal tract. Interest-
ingly, it was previously known that the level of gastrointestinal
eosinophils in a subset of patients with eosinophilic gastrointestinal
inflammation decreases after a specific food elimination diet, but
no causal link between allergen sensitization and exposure and
gastrointestinal eosinophil levels was established (11, 13). Impor-
tantly, we have identified eotaxin as a key regulator of eosinophil
trafficking during gastrointestinal allergic processes. It has previ-
ously been shown that eotaxin has a nonobligatory role in regulating
Fig. 4. Gastrointestinal allergy in IL-5-deficient mice. (A) Eosinophil numbers in the peripheral blood of placebo- and allergen-challenged wild-type and
IL-5-deficient mice. Eosinophil numbers in the peripheral blood of placebo- and allergen-challenged wild-type and IL-5-deficient mice on days 12, 15, and 19 are
shown. (B) Eosinophil numbers in the peripheral blood of placebo- and allergen-challenged wild-type and IL-5-deficient mice on day 19. (C and D) The level of
allergen-specific IgE (C) and IgG1 (D) in serum of placebo- and allergen-challenged wild-type and IL-5-deficient mice. (E) Eosinophil numbers in the jejunum were
quantified by morphometric analysis. Data represent the mean 6 SEM for (A–E) SEM of four to five random sectionsymouse for four to five animals per group
and are representative of two separate experiments. Statistical significance of experimental groups was analyzed by using the unpaired Student’s t test (A). 1,
P , 0.01 compared with placebo-challenged wild-type (WT) mice.









allergic responses in the lung because eosinophil recruitment and
airway hyperreactivity during the sustained late phase response
developed in allergen-challenged eotaxin-deficient mice (9, 10).
Furthermore, antibody neutralization studies with bronchoalveolar
lavage fluid from humans with asthma have suggested only a partial
role for eotaxin in the pathogenesis of asthma (26). In the present
study, allergen-induced eosinophilic infiltration in the gastrointes-
tinal tract was shown to be markedly impaired in the absence of
eotaxin, suggesting that the mechanism for eosinophil homing into
this mucosal tissue differs from that operational in the lung (9, 10).
Only a limited number of experimental systems have been
reported to mimic eosinophilic gastrointestinal diseases. For
example, in one system, anaphylaxis was induced in mice that
were injected with hybridoma cells secreting anti-TNP IgE (37).
These experimental systems, although reporting eosinophilic
inflammation, have not examined the mechanisms involved in
eosinophil trafficking or effector function. Several other gastro-
intestinal allergy models have been reported, but these mimic
noneosinophilic gastrointestinal allergic disorders. For example,
allergen treatment of mice passively sensitized with IgE results
in mast cell-dependent neutrophil recruitment (38). Further-
more, sensitization with allergen and cholera toxin induced mast
cell degranulation and anaphylaxis but no eosinophil recruit-
ment into the gastrointestinal tract (39).
Our data also provide an explanation for the dichotomy that
is often observed between peripheral blood and tissue eosino-
philia in various diseases (40). For example, patients with
gastroesophageal reflux have eosinophilia in the esophagus but
rarely have elevated circulating eosinophil numbers, and only a
subset of patients with asthma has peripheral blood eosinophilia.
Furthermore, drug-induced eosinophilia is usually limited to the
peripheral blood (40). The finding that peripheral blood and
tissue eosinophilia can be dissociated in the absence of eotaxin
indicates that the relative balance between the expression of
eotaxin and eosinophil hematopoietins (e.g., IL-5) can have
profound effects on the relative distribution of eosinophils. As a
corollary, underexpression of IL-5 relative to eotaxin can lead to
gastrointestinal tissue eosinophilia in the absence of circulating
eosinophilia. This is supported by the finding that oral allergen
challenge of mice deficient in IL-5 results in a decrease in the
circulating level of eosinophils compared with wild-type mice.
In summary, this investigation provides insight into the molecular
mechanisms involved in allergic responses of the gastrointestinal
tract. We demonstrate that oral allergen challenge to sensitized
mice promotes allergic inflammation characterized by Th2-
associated eosinophil accumulation in the peripheral blood and
small intestine. Additionally, we demonstrate the critical role of
eotaxin in regulating allergen-induced eosinophil trafficking to the
lamina propria of the gastrointestinal tract. Furthermore, we dem-
onstrate that eosinophil recruitment to the gastrointestinal tract can
occur in the absence of the major eosinophil growth factor IL-5.
Lastly, we provide a molecular explanation to explain the dichot-
omy seen between peripheral blood and tissue eosinophilia in a
variety of medical diseases. These data indicate that agents that
block eotaxin andyor CCR3 may have beneficial effects on mod-
ulating eosinophil-associated gastrointestinal allergies. It is hopeful
that this study will provide the necessary framework to examine
allergic responses in the gastrointestinal tract with the same scrutiny
that has been applied to the study of allergic processes in the lung.
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